Kazakhstan's pharmaceutical market is set to attract new foreign investment, with South Korean investor Kyungdong Pharmaceutical planning to launch production of its medicines in the country, according to infohub.kz.
During President Qasym-Jomart Toqaev's visit to the Republic of Korea, the Ministry of Health signed a memorandum of understanding with Kyungdong Pharmaceutical.
The document provides for the transfer of advanced medical technologies, contract manufacturing and the phased launch of a joint venture to produce medicines in Kazakhstan.
Health Minister Akmaral Alnazarova held talks in person with Kyungdong Pharmaceutical CEO Kim Kyung-hoon.
The two sides discussed prospects for localizing drug production in Kazakhstan, technology transfer, contract manufacturing and the implementation of joint investment projects.
Kyungdong Pharmaceutical is a South Korean pharmaceutical company founded in 1975. It develops, manufactures and sells a wide range of medicines, including both prescription and over-the-counter drugs as well as active pharmaceutical ingredients.
The Health Ministry noted that Kazakhstan's pharmaceutical market totaled $2.5 billion in 2025, while investment in pharmaceutical production reached $142.8 million and exports amounted to $84 million.
Earlier, Kursiv reported that a new full-cycle biopharmaceutical plant will be built in the country. It will be constructed in the Alatau special economic zone in the Almaty Region.